Asia-Pacific Diabetic Retinopathy Market by Type of Treatment (Anti-Vascular Endothelial Growth Factor (VEGF) drug, Intraocular Steroid Injection, Laser Surgery and Vitrectomy), By Indication (Non-Proliferative Diabetic Retinopathy (NPDR) (Mild, Moderate and Severe) and Proliferative Diabetic Retinopathy (PDR)), By End Users (Hospitals, Ophthalmic Clinics and Ambulatory Surgical Centers) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

Asia-Pacific Diabetic Retinopathy Market by Type of Treatment (Anti-Vascular Endothelial Growth Factor (VEGF) drug, Intraocular Steroid Injection, Laser Surgery and Vitrectomy), By Indication (Non-Proliferative Diabetic Retinopathy (NPDR) (Mild, Moderate and Severe) and Proliferative Diabetic Retinopathy (PDR)), By End Users (Hospitals, Ophthalmic Clinics and Ambulatory Surgical Centers) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 939 | Pages: 142 | April 2018 | Region: Asia Pacific


The Asia-Pacific Diabetic Retinopathy Market has been estimated at USD 1.46 billion in 2016 and is projected to reach USD 2.15 billion by 2021, at a CAGR of 7.94% during the forecast period from 2016 to 2021. Asia is predicted to show the wealthy growth in the forecast period. Within the Asian region, western pacific region account for larger share of blindness due to DR when equated to South-East Asia. The major factor contributing to the increasing share of Diabetic Retinopathy among the growing economies are huge pool of patients and increasing support and funding given by the government.

Diabetic retinopathy is considered as a severe sight threatening problem that results due to chronic diabetes. The treatment for diabetic retinopathy may require intraocular injections, anti VEGF drugs, laser surgery or vitrectomy depending on the severity of the condition.

Rapidly expanding diabetic population coupled with increasing awareness of people regarding diabetic retinopathy is expected to drive the growth of global diabetic retinopathy drug market in coming years. Rising medical procedures due to high penetration of medical insurance and rising government initiatives for prevention of diabetes related risks is also believed to garner the growth of retinopathy drug market in future.

The Asia-Pacific Diabetic Retinopathy Market has been segmented on the basis of indication into Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). NPDR is further sub segmented as Mild, Moderate and Severe. Based on Treatment type the market is bifurcated into Anti-Vascular Endothelial Growth Factor (VEGF) drug, Intraocular Steroid Injection, Laser Surgery and Vitrectomy. By end users division is among Hospitals, Ophthalmic Clinics and Ambulatory Surgical Centers. Non-proliferative retinopathy dominated the overall market size estimated to lead the market. Augmented occurrence of diabetes, lack of diagnosis at right time, and non-compliant retinal screening of diabetic patients are predictable to drive the growth of non-proliferative diabetic retinopathy market share. In addition, based on geography the Asia Pacific Diabetic Retinopathy Market is analysed under the regions of India. China, Japan, Australia and South Korea.

The Major companies in Diabetic Retinopathy treatment market are Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd, Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc.

1. Introduction                                                                 

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                           

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                              

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                            

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                     

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                      

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                      

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                               

5. Market Segmentation                                                                              

                5.1 By Type of Treatment                                                            

                                5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug                                          

                                5.1.2 Intraocular Steroid Injection                                           

                                5.1.3 Laser Surgery                                         

                                5.1.4 Vitrectomy                                             

                5.2 By Indication                                                              

                                5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)                                      

                                                5.2.1.1 Mild                       

                                                5.2.1.2 Moderate                            

                                                5.2.1.3 Severe                  

                                5.2.2 Proliferative Diabetic Retinopathy (PDR)                                    

                5.3 By End Users                                                             

                                5.3.1 Hospitals                                  

                                5.3.2 Ophthalmic Clinics                                               

                                5.3.3 Ambulatory Surgical Centers                                           

6. Geographical Analysis                                                                              

                6.3 Asia-Pacific                                                 

                                6.1 Introduction                                              

                                6.2 China                                            

                                6.3 India                                              

                                6.4 Japan                                            

                                6.5 South Korea                               

                                6.6 Australia                                      

7. Strategic Analysis                                                                       

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                      

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                               

                                7.2.5 Competitive Rivalry within the Industry                                      

8. Market Leaders' Analysis                                                                        

                8.1 Bayer AG                                                     

                                8.1.1 Overview                                

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                            

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Pfizer Inc.                                                    

                8.3 Hoffmann-La Roche ltd                                                          

                8.4 Regeneron Pharmaceutical Inc.                                                         

                8.5 Novartis AG                                                

                8.6 Valeant Pharmaceutical International Inc.                                                     

                8.7 Abbott Laboratories Inc.                                                       

                8.8 Alimera Science Inc.                                                                

                8.9 Ampio Pharmaceuticals Inc.                                                

9. Competitive Landscape                                                                           

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                        

                9.3 Agreements, collaborations and Joint Ventures                                                          

                9.4 New Product Launches                                                          

10. Expert Opinions                                                                        

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 

Appendix                                                                           

                a) List of Tables                                                

                b) List of Figures                                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Diabetic Retinopathy Market By Region, From 2016-2021 (USD Billion)
  2. Asia-Pacific Diabetic Retinopathy Market By Treatment Type, From 2016-2021 (USD Billion)
  3. Asia-Pacific Anti-Vascular Endothelial Growth Factor (VEGF) drug Market By Region, From 2016-2021 (USD Billion)
  4. Asia-Pacific Intraocular Steroid Injection Market By Region, From 2016-2021 (USD Billion)
  5. Asia-Pacific Laser Surgery Market By Region, From 2016-2021 (USD Billion)
  6. Asia-Pacific Vitrectomy Market By Region, From 2016-2021 (USD Billion)
  7. Asia-Pacific Diabetic Retinopathy Market By Indication, From 2016-2021 (USD Billion)
  8. Asia-Pacific Non-Proliferative Diabetic Retinopathy (NPDR) Market By Region, From 2016-2021 (USD Billion)
  9. Asia-Pacific Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2016-2021 (USD Billion)
  10. Asia-Pacific Mild Indication Market By Region, From 2016-2021 (USD Billion)
  11. Asia-Pacific Moderate Indication Market By Region, From 2016-2021 (USD Billion)
  12. Asia-Pacific Severe Indication Market By Region, From 2016-2021 (USD Billion)
  13. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market By Region, From 2016-2021 (USD Billion)
  14. Asia-Pacific Diabetic Retinopathy Market By End Users, From 2016-2021 (USD Billion)
  15. Asia-Pacific Hospitals Market By Region, From 2016-2021 (USD Billion)
  16. Asia-Pacific Ophthalmic Clinics Market By Region, From 2016-2021 (USD Billion)
  17. Asia-Pacific Ambulatory Surgical Centers Market By Region, From 2016-2021 (USD Billion)
  18. China Diabetic Retinopathy Market By Treatment Type, From 2016-2021 (USD Billion)
  19. China Diabetic Retinopathy Market By Indication, From 2016-2021 (USD Billion)
  20. China Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2016-2021 (USD Billion)
  21. China Diabetic Retinopathy Market By End Users, From 2016-2021 (USD Billion)
  22. India Diabetic Retinopathy Market By Treatment Type, From 2016-2021 (USD Billion)
  23. India Diabetic Retinopathy Market By Indication, From 2016-2021 (USD Billion)
  24. India Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2016-2021 (USD Billion)
  25. India Diabetic Retinopathy Market By End Users, From 2016-2021 (USD Billion)
  26. Japan Diabetic Retinopathy Market By Treatment Type, From 2016-2021 (USD Billion)
  27. Japan Diabetic Retinopathy Market By Indication, From 2016-2021 (USD Billion)
  28. Japan Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2016-2021 (USD Billion)
  29. Japan Diabetic Retinopathy Market By End Users, From 2016-2021 (USD Billion)
  30. South Korea Diabetic Retinopathy Market By Treatment Type, From 2016-2021 (USD Billion)
  31. South Korea Diabetic Retinopathy Market By Indication, From 2016-2021 (USD Billion)
  32. South Korea Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2016-2021 (USD Billion)
  33. South Korea Diabetic Retinopathy Market By End Users, From 2016-2021 (USD Billion)
  34. Australia Diabetic Retinopathy Market By Treatment Type, From 2016-2021 (USD Billion)
  35. Australia Diabetic Retinopathy Market By Indication, From 2016-2021 (USD Billion)
  36. Australia Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2016-2021 (USD Billion)
  37. Australia Diabetic Retinopathy Market By End Users, From 2016-2021 (USD Billion)
Middle-East & Africa Cardiovascular Therapeutic Drugs By Disease (Arteriosclerosis, Cardiac Arrhythmias, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Artery Disease, Coronary Artery Disease, Hypertensi...
Middle East And Africa Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail...
Latin America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Asia Pacific Clostridium Botulinum Market By Product (botulinum Toxin Type A And Botulinum Toxin Type B), By End User (aesthetic And Therapeutics), By Distribution Channel (hospitals, Clinics And Retail Pharmacies) ...
Europe Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And...
North America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And By Reg...
The Dental Bone Graft Substitutes Market Is Predicted To Reach USD 664.3 Million With A CAGR Of 9.8% According To Market Data Forecast Report....
Middle East And Africa Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal D...
Latin America Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Reg...
Asia-Pacific Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Rege...
Europe Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Regenerati...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.